Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis

Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis Magdalena Kajdos, Jacek Szymański, Hanna Jerczyńska, Tomasz Stetkiewicz, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1707582/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 5 You are reading this latest preprint version Abstract Purpose: Angiogenesis is engaged in endometriosis. It is regulated by regulatory factors and cytokines, transported in microvesicles. The purpose was to investigate the presence of MVs with vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP – 9) in peripheral blood and peritoneal fluid of women operated on for endometrioma or teratoma Material and method: Microvesicles (MVs) were determined in blood samples and peritoneal fluid samples collected from women aged 20-60 years operated on for endometriosis (test group) and teratoma (control group). The final investigations were performed on 47 patients, who qualified for the study based on the meticulous inclusion criteria. MVs were analyzed by flow cytometry (FACS) using annexin V, antibodies for molecules characteristic of cells from endometriosis foci (keratin 18 (K18), CD105, CD146), and antibodies for intraepithelial vascular growth factor VEGF and metalloproteinase - 9 (MMP - 9). The sample was double “reading” using flow cytometry (FACSCantoII). Results: Cytometry analysis confirmed MVs’ presence in plasma and peritoneal fluid collected from patients with both endometriosis and teratomas. A statistically significant higher level of AnnexinV (+) MVs were observed in plasma samples of endometriosis patients. In the control group, there was a higher percentage of double-positive VEGF (+) / MMP9 (+) and single MMP9 (+) positive MVs in the serum. In the peritoneal fluid higher frequency of double-positive VEGF (+),/MMP9 (+) MVs were found in the control group. However, the amount of VEGF (+) / MMP9 (+) MVs object did not enable to differentiate between the test and control groups. The study was the first, in which MVs were confirmed in plasma and peritoneal fluid in benign adnexa tumors. Conclusion : Microvesicles are present in peripheral blood and peritoneal fluid samples collected from patients with endometriosis and teratomas. Microvesicles with proangiogenic factors (VEGF and MMP-9) are more abundant in blood and peritoneal fluid samples from patients with teratomas. endometriosis microvesicles angiogenesis VEGF MMP-9 Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 1. Introduction Endometriosis is a common gynecological disorder defined by the proliferation of endometrial glands and stroma outside the normal uterine cavity [ 1 ]. It affects especially women of reproductive age, but girls before menarche and postmenopausal women are occasionally diagnosed as well [ 2 ]. 20–50% infertile women suffer from endometriosis [ 1 , 2 ]. The physical, mental and social well–being is reduced significantly. Clinical manifestation of endometriosis is not characteristic. The disease can be asymptomatic; however, permanent or temporary pain is common. Dysmenorrhea, dyspareunia, and infertility are the typical and common triad of endometriosis symptoms [ 106 ]. The symptoms also depend on the localization of ectopic endometrial lesions. Endometrial implants in the peritoneum of recto-uterine and vesicouterine excavation, Sacro-uterine ligaments, and rectovaginal septum cause pain and bleeding during urination and defecation, pain in the sacral spine, and pain radiating to the thighs. However, ovaries, fallopian tubes, and pelvic and abdominal peritoneum are more common localization for endometrial implants. Chocolate cysts filled with hemolyzed blood are a typical sign of ovarian endometriosis. Endometrial glands and stroma can grow into the myometrium layer and lead to uterine muscle tissue changes called adenomyosis. Extra pelvic endometriosis is rare and occurs in well-vascularized organs, for example, the intestine, lung, or brain [ 3 – 5 ]. The pathogenesis of endometriosis remains unclear. Many theories explain how endometrial implants form, but neither describes this process clearly. Retrograde menstruation is accepted as the most plausible sequence of events leading to lesions establishment [ 1 , 6 – 8 ] According to the new hypothesis, endometriosis could also originate from endometrial stem cells or mesenchymal stem cells from the bone marrow homing peritoneal cavity and differentiating into endometrial cells. The viable endometrial cells spread and attach to the peritoneal surface. The success of the ectopic implants depends on the inflammatory response, neoangiogenesis, fibrosis, adhesion formation, avoidance of apoptosis, immune dysfunction of the host, and neuronal infiltration [ 3 , 9 – 13 ]. The exact pathological mechanisms are observed both in endometriosis and neoplastic disease. Angiogenesis is one of the critical steps engaged in those pathologies. 1.1. Role of angiogenesis in endometriosis pathogenesis Angiogenesis is a multistep process of forming new blood vessels and occurs both in physiological and pathological conditions. The new blood vessels form by budding endothelial cells into the extracellular matrix, which is strictly regulated. Endothelial cells and other cells (e.g., macrophages, neoplastic cells) release growth factors characterize for angiogenesis (VEGF, bFGF) to degrade the existing vessel’s wall. VEGF ( vascular endothelial growth factor ) is the main proangiogenic factor. It influences endothelial cells’ proliferation, migration, and apoptosis. Activated endothelial cells release proteolytic enzymes to degrade the base membrane allowing more effortless movement of cells. Metalloproteinases (enzymes modeling matrix) cause changes in the composition of the base membrane. Metalloproteinases modify the extracellular matrix to promote the migration of epithelial cells and the process of neovascularization [ 14 , 15 ]. Cells combine to form capillary buds. A synthesis of base membrane components and the development of the other layers of the vessel produces further stabilization of the vessel. The web of blood vessels surrounding endometriosis foci is characteristic of this disease and confirmed in microscopic studies [ 1 ]. Cells of ectopic endometrium, immune cells, and mesothelium cells release the growth factors and proteolytic enzymes into the peritoneal cavity. Macrophages and mast cells from peritoneal fluid and endometriosis foci are the primary sources of VEGF [ 16 – 19 ]. Increased concentration of the soluble form of VEGF was observed in peritoneal fluid collected from patients with advanced endometriosis [1,218,20–22]. Some studies also demonstrated the highest concentration of VEGF in endometrial cysts and red implants [ 3 , 23 , 24 ]. The expression of VEGF, VEGF-2, and the number of activated macrophages correlates to the expression of metalloproteinase 9 in both peritoneal fluid and endometrial implants [ 14 , 15 ]. Moreover increased amount of metalloproteinases MMP-2, MMP-3, MMP-7, and MMP-9 is observed in patients with endometriosis [ 25 – 27 ]. This fact confirms enhanced proteolysis in ectopic endometrium [ 25 ]. 1.2. Role of peritoneal fluid in endometriosis pathogenesis Peritoneal fluid is the most critical factor controlling the peritoneal cavity microenvironment and is observed in physiological and pathological conditions. Physiologically, peritoneal fluid ranges from 5 to 20 ml in size, and the amount depends on the menstrual cycle phase. Its production increases in endometriosis and infertility [ 28 – 31 ]. The fluid arises through plasma filtration, the ovaries secretion, tubal mucus production, retrograde menstruation, and macrophages activity to produce and secrete proinflammatory cytokines/chemokines. It contains cells elements (macrophages, natural killers cells, lymphocytes, eosinophils, mast cells, and mesothelial cells) and substances they produce (cytokines, prostaglandins, hydrolytic enzymes, complement components, and oxygen free radicals) [ 31 ]. Changes in the composition of peritoneal fluid in endometriosis result from immune responses and their direct contact with the endometrial implants. Chronic inflammation in the pelvic cavity is a consequence of humoral and cell-mediated responses. The concentration of T cells increases, followed by the increase of the T-helper / T-suppressor ratio[ 32 ]. The number of NK cells responsible for removing ectopic endometrial cells increases. However, they are dysfunctional and fail to kill ectopic implants [ 32 – 36 ]. A significant rise in macrophages is observed, and the cells demonstrate higher activin than macrophages from healthy women [ 31 ]. Macrophages and cells of endometrial implants produce the following cytokines: IL-8, IL-10, ICAM-1, MCP-1, RANTES, VEGF, IGF, EGF, M-CSF, HGF, which are found in higher concentrations in the peritoneal fluid [ 32 ]. This fact confirms the existence of subclinical inflammation inside the peritoneal cavity. Immunological and angiogenic factors present in the pelvic environment participate in the pathogenesis of endometriosis [ 32 ]. 1.3. Microvesicles Extracellular vesicles were described in 1967 by Wolf [ 40 ] as waste products of the human body. Further studies showed that cells could release more different vesicles and apoptotic bodies, exosomes, and microvesicles (MVs). Microvesicles have different shapes ranging from 100 to 1,000 nm in size [ 37 – 39 ]. The shape and size depend on MVs’ origin and function. Regulated release from outward budding or blebbing on the plasma membrane [ 1 ] causes the formation of the MVs. Health cells shed MVs from selected areas, whereas tumor cells from the entire surface [ 1 ]. Specific markers for MVs have not been identified yet. Previous research has used selectins, integrins, flotillin-2, CD-40, and metalloproteinase [ 37 , 41 , 42 ]. The release of MVs was confirmed in normal cells types, including red blood cells, platelets, endothelial cells, and pathological mostly cancer cells [ 37 , 43 – 45 ]. Microvesicles can transport enzymes, regulatory and growth factors, cytokines, lipids, and nucleic acid (mRNA, miRNA, ncRNA, genomic DNA) [ 8 , 37 , 46 – 50 ]. They are responsible for homeostasis in human organisms and the induction of pathological processes. Proteolytic enzymes and proangiogenic factors play a role in creating new vessels. They are the MVs’ cargo, as confirmed in cancer, and could in similar promote and regulate the creation of new endometrial implants. Moreover, MVs with regulatory factors could theoretically induce the tolerance against foci of ectopic endometrium and mediate angiogenesis. That was the assumption leading to the start of the study. 2. Objectives Time from first symptoms to the final diagnosis of endometriosis is essential. Nowadays, it takes from 7 to 11 years [ 51 – 54 ]. Diagnosis is based on clinical signs; however, surgery and histological examination are the strongest confirmation Clinicians are recommended to use imaging (US or MRI) in the diagnostic work-up for endometriosis, but they need to be aware that a negative finding does not exclude endometriosis, particularly superficial peritoneal disease [ 108 ]. It explains why new diagnostic tools are needed. Blood markers have not been found yet. Our study was conducted to find microvesicles in peripheral blood and peritoneal fluid collected from women with benign ovarian lesions like ovarian endometrioma or teratoma. Teratoma is a germ cells tumor that differentiates toward somatic-type cell populations [ 107 ]. If the presence of MVs is confirmed, we decided to investigate if they were filled with essential angiogenesis mediators, like vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9). Previous research revealed a higher VEGF in peritoneal fluid and foci of ectopic endometrium [ 18 , 55 ]. The same observation concerned metalloproteinases 9 and 2 [ 25 ]. In addition, the correlation between MMP-9 and VEGF in endometriosis foci was found [ 56 ]. However, the transport of VEGF and MMP-9 in MVs has never been studied both in endometriosis and teratoma. 3. Materials And Methods The study was conducted in Dept. of Gynecology and Gynecologic Oncology PMHCRI from 2014 to 2017 based on two grants (NCN UMO-2014/13/D/N/Z5/00446 – “Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis”; Young Researcher PMHCRI Grant – “Microvesicles as a potential biomarker of endometriosis”). The isolation technique was tested and finally established during the preliminary phase of the study provided by Young Researcher Grant. The Ethical Commission of the Polish Mother Memorial Hospital Research Institute approved all studies (decision number 40/2013). 3.1. Patients The patients operated on for benign lesions of ovaries in PMHCRI were qualified for the study. All patients were given information about endometriosis and signed informed consent. Forty-seven women aged 20–60 took part in the study. Women operated on for endometriosis were the test group, whereas women with teratoma formed the control group. Moreover, patients with chronic diseases such as cardiac problems (blood hypertension, ischemic heart disease), thyroid diseases, and autoimmune diseases (Hashimoto’s disease, psoriasis, atopic dermatitis, lupus, Crohn’s disease, celiac disease) were excluded from the research due to the observations that MVs could be present and play a role in the pathogenesis of these diseases. Clinical presentation and ultrasound examination determined patients’ qualifications for to test or control group. The ovarian lesions were firstly examined using ultrasound performed by a doctor having great experience in ultrasonography. The doctor performed gynecological ultrasounds in PMHCRI for many years. During this time he saw different cases of endometriosis and other gynecological diseases. That gives him the qualification to diagnose even small endometrial lesions, difficult to see for others. However, the diagnosis was confirmed during operation and finally in histopathological examination. 3.2. Samples Microvesicles (MVs) were determined in samples of 5 ml blood and samples of 5 ml peritoneal fluid. The blood samples were collected upon admission while taking the blood sample for preoperative test. The fluid was collected from the peritoneal cavity during the g operation. Blood and peritoneal fluid samples were dispensed into tubes containing trisodium citrate solution serving as an anticoagulant. Blood samples were collected through a 16 gauge needle (S-Monovette®-Needle) into a syringe (S-Monovette® 5ml, Citrate 3.2% (0.106mol/l)). Peritoneal fluid samples were collected at the beginning of operations. Fluid from the Douglas pouch was collected through a laparoscopic needle into a sterilized syringe. It was done after abdominal cavity insufflation when a camera and trocars were put through the abdominal wall. Fluid from the sterilized syringe was put into a blood collecting tube with 3.2% Na Citrate (5ml volume). Samples of peritoneal fluid were not collected from all patients undergoing operations because either the fluid was not found or its amount was too small to collect. Thirty samples of plasma and 27 samples of peritoneal fluid were collected. Plasma samples were collected from 23 patients with endometriosis (test group) and seven patients with teratoma (control group); twenty-seven peritoneal fluid samples were collected: 19 in the test group and 8 in the control group. Both peritoneal fluid and plasma were collected from 10 patients (7 in the test group and 3 in the control group). Table 1 presents the distribution of patients the in test and control group. Table 1. Distribution of patients in test and control groups. (Table is explained in the text above) All patients PFP Peritoneal fluid PFP and peritoneal fluid Test group 35 23 19 7 Control group 12 7 8 3 Both group 47 30 27 10 PFP – platelet free plasma 3.3. MVs isolation and samples storage Samples of blood and peritoneal fluid have undergone the process of getting platelet-free plasma (PFP)/platelet-free peritoneal fluid. The method was developed in the Central Research Laboratory (CoreLab) of Medical University in Lodz and is based on previously published studies [ 73 , 76 ]. The first stage was performed in PMHCRI. The samples underwent centrifugation to remove platelets, erythrocytes, and other large fragments, which could interfere with subsequent analysis. The platelet free plasma (PFP) was prepared from a solution of anticoagulant and blood through singular centrifugation at 3000xg for 15 minutes in angle–headed rotor. The centrifugation to isolate MVs was performed in less than thirty minutes after blood and peritoneal fluid collection. PFP was collected from sediment and stored in special tubes for freezing. Samples of peritoneal fluid with anticoagulants have undergone the same process of centrifugation. Supernatant formed during centrifugation was collected as platelet-free peritoneal fluid. It was stored in tubes fit to freeze at minus 40 o Celsius. All samples (PFP/platelet free peritoneal fluid) were frozen at minus 40 o Celsius after centrifugation and stored for subsequent analysis. The second stage of MV’s isolation was performed in the Central Research Laboratory of Medical University in Lodz. Frozen samples of PFP and platelet-free peritoneal fluid were transported in an icebox to protect them from thaw and put at the same temperature (-40℃). Frozen aliquots (2ml) were thawed at ambient temperature for 20–30 minutes and mixed well but delicately to limit the possible extent of in vitro MVs generation. Different times and speeds were tested to choose the optimal conditions. Data was not shown, due to the large number of them. Moreover, their presentation will not improve the value of our publication. Optimal conditions did not cause substantial loss of MVs but let pellet bigger debris. From each sample, portions of 2 x 650µl were taken and centrifuged at 1000 x g for 5 minutes in a commonly used tabletop centrifuge (Eppendorf). To prepare the sample for further processing, 500µl of supernatant was taken from each portion, then combined and mixed gently in one Eppendorf tube. As the next step, 100 µl aliquots of isolated MVs were used. 3.4. Antibodies and Incubation The study used six types of antibodies. Annexin V was chosen as a substance commonly used to stain MVs in previous research. One of the study assumptions was finding MVs revealed from ectopic endometrium cells (endometriosis focus). Antibodies for CD105, CD146, and cytokeratin (CK 18) were used to confirm this thesis. Those structures were found on the endometrial cell surface. Antibodies for VEGF and MMP-9 were the last group. Their presence inside microvesicles could confirm MVs’ role in angiogenesis – one of the main processes observed in endometriosis development. Aliquots of microvesicles (100 µl) were incubated at room temperature with proper antibodies for 25–30 minutes, protected from light. Three sets of antibodies mixtures were prepared: Set 1: Annexin V (5µl + 13µl buffer), CK 18 (10µl), MMP – 9 (2 µl) and VEGF (10 µl) Set 2: Annexin V (5µl + 13µl buffer), CD 105 (10µl), MMP – 9 (2 µl) and VEGF (10 µl) Set 3: Annexin V (5µl + 13µl buffer), CD 146 (10µl), MMP – 9 (2 µl) and VEGF (10 µl) Stained samples were analyzed after setting the correct conditions. Three sets of four monoclonal antibodies were created to reduce possible interference. The sets (set 1, set 2, set 3) differed in the molecule found on the surface of endometrial cells (CK18, CD105, CD146, respectively) [Table 2 ]. Objects with a different arrangement of monoclonal antibodies were counted in each set [Table 3 ]. Moreover, objects positively for single monoclonal antibodies were counted. Table 2 Sets of four monoclonal antibodies Set 1 CK 18 + AnnexinV + VEGF + MMP-9 Set 2 CD 105 + AnnexinV + VEGF + MMP-9 Set 3 CD 146 + AnnexinV + VEGF + MMP-9 CK 18 – cytokeratin 18, VEGF - Vascular Endothelial Growth Factor, MMP-9 – metalloproteinase 9 Table 3 Different confirmation of monoclonal antibodies in set 1, set 2, set 3 Set 1 Set 2 Set 3 VEGF+/MMP9+ VEGF+/MMP9+ VEGF+/MMP9+ All+(AnnexinV+/CK18+) All + 1(AnnexinV+/CD105+) All+-1(AnnexinV+/CD146+) AnnexinV+/MMP9+ AnnexinV+/MMP9+ AnnexinV+/MMP9+ Allq+(VEGF+/CK18+) Allq+-1(VEGF+/CD105+) Allq+-1(VEGF+/CD146+) AnnexinV+/CK18+ AnnexinV+/CD105+ AnnexinV+/CD146+ VEGF+/CK18+ VEGF+/CD105 VEGF+/CD146 CK18+/MMP-9+ CD105+/MMP-9+ CD146+/MMP-9+ CK 18 – cytokeratin 18, VEGF - Vascular Endothelial Growth Factor, MMP-9 – metalloproteinase 9 3.5. Flow Cytometry FACSCanto II Biosciences cytometer was used to analyze MVs in peripheral blood and peritoneal fluid collected from women with benign ovarian lesions (endometriosis and teratomas). Proper gating was set up for structures as small as MVs. Specialized beads were used to achieve it (Megamix – SSC Biocytex). They had a similar size to microvesicles. Their size was ranging from 0.1 µm to 1 µm. MVs stained by monoclonal antibodies were analyzed after setting the correct gate. The obtained data were quantified and plotted using the BD FACSDiva software (Becton Dickinson). Data on events ranging in size from 0.22 µm to 0.24 µm (220–240 nm) were analyzed statistically. The obtained data were quantified and plotted. An example of a two-dimensional scatter plot is presented below (Fig. 1 and Fig. 2), and the explanation is in Table number 4. Table 4 Explanation of two-dimensional scatters plot. All Rectangle with yellow frame shows all events detected by flow cytometry 05 − 1/024 Rectangle with blue frame shows events in size bigger than 0.24 µm (240nm) 05 − 1/02 Rectangle with red frame shows events in size from 0.20 µm (200 nm) 3.5. Statistical analysis STATISTICA was used to analyze obtained results. Median, 1st, and 3rd quartiles were counted for each type of mark in individual sets (set 1, set 2, set 3) and in each subgroup of patients. Median gave the average value in patients groups, whereas 1st and 3rd quartiles measured the scatter of results. Mann–Whitney’s test was used to compare both groups of patients. The null hypothesis was that analyzed data were from the same population or population with identical medians. p Values lower than 0.05 allowed to reject the null hypothesis with a significance level of 0.05 and accept the alternative theory that the medians in the groups are different. Moreover, the correlation of MVs amount in plasma and peritoneal fluid was checked. The clustering of patients within groups (plasma and peritoneal fluid) was performed to show the cytometry results between groups. Logistic regression was used to predict from MVs profile whether the patient was in the test or control group. 4. Results Cytometry analysis confirmed MVs’ presence in plasma and peritoneal fluid collected from patients with endometriosis and teratomas. A statistically significant higher level of AnnexinV (+) MVs were observed in plasma samples of endometriosis patients (Fig. 3). In the teratoma group, there was a significant percentage of double-positive VEGF (+) / MMP9 (+) (Fig. 4) and single MMP9 (+) positive MVs in the serum (Fig. 5). The error bars, in Figs. 3 to 5, shoved standard deviation. Moreover, the above differences are summarized in Table 5. In the peritoneal fluid higher frequency of double-positive VEGF (+), / MMP9 (+) MVs were found in the control group. However, the amount of VEGF (+) / MMP9 (+) MVs object did not differentiate between the test and control groups (Fig. 6). The above differences are summarized in Table 6. 4. Discussion The study was the first in which MVs were confirmed in plasma and peritoneal fluid in benign conditions like endometriosis and teratoma. Different MVs are found in both physiological conditions and healthy bodies and diseases [ 57 – 60 ]. Studies in which MVs have been analyzed in gynecological disorders are not common. Researchers focused mostly on MVs present in ascites that accompany ovarian cancer, not on the MVs population in the benign lesions. It is worth mentioning that the study group was the biggest group of patients with gynecological diseases, in which MVs were studied. Despite the fact, that the strict exclusion criteria influenced negatively the study participants numbers. Ten patients were excluded because of abnormal levels of thyroid gland hormones. Further tests confirmed hypothyroidism or Hashimoto’s disease. MVs increase is observed in autoimmunological diseases [ 61 – 63 ], kidney disorders [ 6 , 4 ], and vascular diseases [ 65 ]. MVs take part in immunological response through antigens transport and presentation [ 66 – 67 ]. Microvesicles are also described as proinflammation mediators [ 66 ]. Based on those facts, patients with endocrine disorders and infections were not qualified for the study. Microvesicles are also observed in cardiological problems, such as hypertension or atherosclerosis disease. MVs with procoagulant features are released from monocytes and can induce a formation of an atherosclerotic plaque [ 68 , 69 , 97 ]. MVs have influenced deterioration of the renal function in patients with hypertension [ 70 , 71 , 97 ]. We hoped to collect peritoneal fluid from every operated patient, but the peritoneal fluid was not found in every case. This fact made it impossible to check correlations between MVs numbers in peritoneal fluid and peripheral blood. Moreover, peritoneal fluid contaminated by blood or chocolate cysts could not be used. First centrifugation of blood and peritoneal fluid samples was performed within 30 minutes from samples collection. Time range was vital because we wanted to analyze MVs presented in blood and peritoneal fluid at the moment of collection. Prior studies showed that MVs are released from activated cells in vitro [ 72 ]. Moreover, the correlation between MVs amount and time from collection of blood samples was observed [ 73 ]. The same assumption was made for the collection of peritoneal fluid samples. Microvesicles were not analyzed in peritoneal fluid in non-oncological diseases previously. Studies were performed on specimens collected from patients with ascites. The composition of ascites fluid differs from the peritoneal fluid. The differences are shown in cells, proteins, macro, and microelements [ 74 , 75 ]. Moreover, the peritoneal fluid composition is different from blood. It contains cells not observed in the blood, such as endometrial cells, adipocytes, and mesothelial cells. The centrifugated samples were frozen to minus 40℃, which allowed safe storage and transport. Witwer et al. froze FPF at minus 80℃, but Jayachandran et al. revealed that freezing in higher temperatures did not influence MVs composition and amount [ 73 , 76 ]. Moreover, the negative effect of dehydration was avoided [ 76 ]. Choice of isolation method was not easy because methods of MVs isolation are not united and standardized [ 77 , 78 ]. Many researchers tried different times and speeds of centrifugation to get the optimal amount of microvesicles. Utracentrifuges were also used; however, they led to a new MVs generation. We wanted to avoid that. We followed the methodology described by the papers in which MVs released from platelets, leukocytes, and epithelial cells were analyzed [ 79 – 85 ]. Based on them, we decided to reduce the number of centrifugation after samples defrosting. More than one centrifugation did not give a statistically significant difference in MVs amount [ 86 ]. Moreover, the speed was reduced, resulting in more MVs [ 79 ]. Shah MD et al. also showed more MVs originated from epithelial cells when they used a shorter time of centrifugation [ 85 ]. In prior studies, optical and non-optical methods were used to analyze small subjects like microvesicles. More research was conducted with flow cytometry than with TEM (transmission electron microscope) and AFM (atomic force microscope). Despite TEM and AFM having higher resolution, the process of MVs isolation is more complicated and requires a restrictive condition of samples preparation [ 78 ]. In flow cytometry, it is possible to measure the intensity of scattered light and fluorescence of a singular subject in a hydrodynamically focused fluid stream [ 80 ]. In addition, the results of flow cytometry analysis are repeatable and plausible [ 87 ]. The release of MVs from endothelium and epithelium cells was confirmed previously [ 57 – 60 ]. Based on those facts, we assumed that endometrium had adequate abilities. MVs were stained by monoclonal antibodies for cytokeratin 18, CD 105, and CD 146, typical markers for endometrial cells. Bokor et al. analyzed the cells composition of peritoneal fluid collected from women with endometriosis. They revealed cells with cytokeratins 18, 19, and vimentin in PF [ 90 ] which explained retrograded menstruation as a cause of endometriosis. Linden et al. also analyzed peritoneal fluid composition in endometriosis. They found endometrial cells positive for CK 18 in both groups of patients, one with endometriosis and the other without [ 91 ]. In this research, we observed more subjects with CK18 positive in PF in both groups of patients. Antibodies characteristic of endometrium were chosen to mark MVs in peritoneal fluid and blood samples. The choice was made based on previous studies. Zhang et al. observed the increase of CD105 on endothelial cells in small vessels in the endometrium [ 92 ]. Moreover, the expression of CD105 and CD146 was observed in the endometrium and its stroma [ 92 , 93 ]. Annexin V was widely used as a marker for microvesicles released from most types of cells in the human body [ 94 – 96 ]. This research suggests the presence of MVs annexin V positive but not in all sets. The absence of MVs annexin V positive is surprising and it might suggest that not all MVs contain phosphatidylserine [ 98 – 101 ]. Endometriosis development depends on a web of new vessels. Endothelial cells are stimulated by growth factors to proliferation, whereas enzymes change the extrauterine matrix to make more space for new vessels. Endometrium epithelium cells can release vesicles, which transfer molecules to the endometrium, also the ectopic one too [ 103 ]. Harper et. al isolated microvesicles in samples of endometrium collected from healthy individuals and patients with endometriosis [ 105 ]. VEGF and MMP-9 as angiogenesis markers should be observed in MVs analyzed in FPF and PF collected in the test group. However, MVs stained antibodies for VEGF and MMP-9 were found in set 3 in both media collected in the control group. Moreover, more MVs with single antibodies for MMP-9 were found in the same group of patients. It could indicate intensive angiogenesis in benign ovarian lesions such as teratomas. Tao et al. had similar results in their study of the VEGF/VEGFR2 trail of angiogenesis [ 102 ]. Several studies focused on miRNAs enabled to regulate angiogenesis. The regulation is based on the influence on VEGF-A production [ 104 ]. Higher expression of miR16 − 5p, miR-138, miR-29c-3p, and miR-424 − 5p was shown in endometriosis [ 104 ] The strength of the study is the strict exclusion criteria and the methodology based both on the literature and personal testing of different conditions to optimize the MVs harvest. The weakness is the fact that based on the results it was not possible to bring patients under the category of endometriosis or teratoma. Even though the groups have been the greatest studied so far, it occurs that they could be too small to show properly the differences between the groups based on the peritoneal fluid samples. 5. Conclusions Microvesicles are present in peripheral blood and peritoneal fluid samples collected from patients with endometriosis and teratoma. Microvesicles with proangiogenic factors (VEGF and MMP-9) are more commonly observed in blood and peritoneal fluid samples from patients with teratoma. Declarations Author Contributions All authors have read and agreed to the published version of the manuscript Conflicts of Interest: “The authors declare no conflict of interest References Giusti I, D'Ascenzo S, Dolo V (2013) Microvesicles as Potential Ovarian Cancer Biomarkers, Biomed Res Int. ; 2013:703048 Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ (2001) Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types Int. J Gynecol Pathol 20:133139 Hadfield RM, Mardon HJ, Barlow DH, Kennedy SH (1997) : Endometriosis in monozygotic twins; Fertil Steril. Nov;68(5):941-2 Lauchlan SC (1972) The secondary Müllerian system. Obstet Gynecol Surv 27:133 Inal JM et al (2013) Blood/plasma secretome and microvesicles,Biochim. Biophys. Acta Meckes DG Jr, Raab-Traub N (2011 Dec) Microvesicles and viral infection. J Virol 85(24):12844–12854 Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, Araoz PA, Budoff MJ, Harman SM, Miller VM (2008 Sep) Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 295(3):H931–H938 D'Souza-Schorey C, Clancy JW Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.Genes Dev. 2012 Jun15;26(12):1287–99 Frey GH, Bluefield WV (1957) The familial occurrence of endometriosis. Am J Obstet Gynecol 73:418–422 Gardiner L Endometriosis. Obstet Gynecol 1953, 1, 615 Ranney B, Endometriosis IV (1971) Hereditary tendency. Obstet Gynecol 37:734–737 Practise Committee of American Society for Reproductive Medicine (2006) Endometr infertility Fertil Steril 86:S156–160 Bulun SE, Endometriosis (2009) N Engl J Med 360:268279 Hu Z, Mamillapalli R, Taylor HS (2019) Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis. Am J Physiol Endocrinol Metab 316:E373–E382 Saha R, Pettersson HJ, Svedberg P, Olovsson M, Bergqvist A, Marions L, Tornvall P, Kuja-Halkola R (2015 Oct) :.Heritability of endometriosis, Fertil Steril. 104:947–9524 Wilczyński JR, Szyłło S (2013)K., Elsevier Urban & Partner, Wrocław. ;:47–55 Kyama CM, Debrock S, Mwenda JM, D’Hooghe TM (2003) Potential involvement of the immune system in the development of endometriosis. Reproad Biol Endocrinol 1:123–132 McLaren J, Prentice A, Charnock-Jones DS et al (1996) Vascular Endothelial Growth Factor Is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroides. J Clin Invest 98:482–489 Tariverdian N, Theoharides TC, Siedentopf F et al Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach.Semin Immunopathol207, 29,193–210 Gargett CE, Masuda H (2010) Adult stem cells in the endometrium. Molec Hum Reprod 16(11):818–834 Shifren JL, Tseng JF, Zaloudek CJ et al (1996) Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J of Clinl Endocrin and Metabol 81(8):3112–3118 Mueller MD, Lebovic DI, Garrett E, Taylor RN (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 74(1):107–112 Merrill JA (1966) Endometrial induction of endometriosis across Millipore filters. AmJObstetGynecol 94:780–790 Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:5898–5905 Radowicki S, Szyłło K (2013) : Endometrioza, diagnostyka i leczenia, (2), 6–18 Forehand JR, Johnston RB, Bomalski JS (1993) Phospholipase A2 activity in human neutrophils. J Immunol 151:4918–4925 Garcie-Velasco JA, Arici A (1999) interleukin-8 stimulates the adhesion of endometrial stroma cells to fibronectin. Fertil Steril 72:336–340 Koninckx PR, Kennedy SH, Barlow DH (1999) Pathogenesis of endometriosis: the role of peritoneal fluid. Gynecol Obstet Invest 47:23–33 Maathuis JB, Van Pf L, Michie EA (1978) Changes in volume, total protein and ovarian steroid concentration of peritoneal fluid throughout the human menstrual cycle. J Endocrinol 76:123–133 Syrop CH, Halme J (1987) Peritoneal fluid environment and infertility. Fertil Steril 48:1–9 Polak G, Kotarski J (2013) The role of peritoneal fluid in pathogenesis of endometriosis,Endometriosis. Diagnosis and Treatment1–5 van der Linden PJ (1996) Theories on the pathogenesis of endometriosis. Hum Reprod Oxf Engl 11(Suppl 3):53–65 Taylor RN, Yu J, Torres PB et al (2009) Mechanistic and Therapeutic Implication of Angiogenesis in Endometriosis. Reprod Sci1 16:140–146 Laganà AS, Garzon S, Götte M, Viganò P, Franchi M, Ghezzi F, Martin DC (2019) The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights. Int J Mol Sci 20:5615 Waldeyer H “Die epithelialen Eierstockgeschwülste.” Ins besonders die Kystome: The epithelial ovarian tumors, especially the cystic tumors).Arch Gynäkol1870, 1,252–316 Miyazaki K, Dyson MT, Coon V, Furukawa JS, Yilmaz Y, Maruyama BD, Bulun T (2018) Generation of Progesterone-Responsive Endometrial Stromal Fibroblasts from Human Induced Pluripotent Stem Cells: Role of the WNT/CTNNB1 Pathway. Stem Cell Rep 11:1136–1155 Moen MH, Magnus P (1993) The familial risk of endometriosis. Acta Obstet Gynecol Scand 72:560–564 Simpson JL, Elias S, Malinak LR, Buttram VC (1980) Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 137:327–331 Maliniak LR, ButtramVC, Elias S, Simpson JL (1980) Heritable aspects of endometriosis. II. Clinical characteristics of familial endometriosis. Am J Obstet Gynecol 137:332–338 Wolf P (1967) The nature and significance of platelet products in human plasma. Br J Haematol 13:269–288 Dos Reis DM, de Sa MF, de Moura MD et al (1999) Familial risk among patient with endometriosis. J Assist Reprod Genet 16:500–503 Kashima K, Ishimaru T, Okamura H et al (2004) Familial risk among Japanese patient with endometriosis. Int J Gynaecol Obstet 84:61–64 Stefansson H, Geirsson RT, Steinthorsdottir V et al (2002) Genetic factors contribute to the risk of developing endometriosis. Hum Reprod 17:555–559 Zondervan KT, Weeks DE, Colman R et al (2004) Familial aggregation of endometriosis in large pedigree of rhesus macaques. Hum Rerod 19:448–455 Albertsen HM, Chettier R, Farrington P, Ward K (2013) Genome-wide association study link novel loci to endometriosis. PLoS ONE 8:e58257 Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Export Rev Proteomics 6:267–283 Hugel B, Martínez MC, Kunzelmann C, Freyssinet JM (2005) Membrane microparticles: two sides of the coin, Physiology, vol. 20, pp. 22–27, Valadi H, Ekstrom K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659 Skog J, Wurdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476 Pisetsky DS, Gauley J, Ullal AJ (2010) Microparticles as asource of extracellular DNA. Immunol Res Irungu S, Mavrelos D, Worthington J, Blyuss O, Saridogan E, Timms JF (2019 Apr) Discovery of non-invasive biomarkers for the diagnosis of endometriosis. Clin Proteom 6:16:14 Ballard K, Lowton K, Wright J (2006) What’s the delay? A qualitative study of women’s experiences of reaching a diagnosis of endometriosis. Fertil Steril 86(5):1296–1301 Hadfield R, Mardon H, Barlow D, Kennedy S (1996) Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK. Hum Reprod 11(4):878–880 Husby GK, Haugen RS, Moen MH (2003) Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 82(7):649–653 Kayama CM, Debrock S, Mwenda JM, D’Hooghe TM (2003) Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 1:123–132 Machado DE, Berardo PT, Palmero CY, Nasciutti LE (2010) Higher expression of vascular endothelial growth factor (VEGF) and35. its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is smaller to cancer disease. J Exp Clin Cancer Res 29:4–13 Dziechciowski M, Zapala B, Skotniczny K et al (2018) Diagnostic and prognostic relevance of microparticles in peripheral and uterine blood of patients with endometrial cancer. Ginekol Pol 89(12):682–687 Mancuso P, Calleri A, Cassi C et al (2003) Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522:83–97 Beerepoot LV, Mehra N, Vermaat JSP et al (2004) Increased levels of viable circu-lating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1):139–145 Mancuso P, Burlini A, Pruneri G et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97(11):3658–3661 Nielsen CT, Ostergaard O, Stener L, Iversen LV, Truedsson L, Gullstrand B et al (2012) Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum 64:1227 Biro E, Nieuwland R, Tak PP, Pronk LM, Schaap MCL, Sturk A et al (2007) Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 66:1085 van Eijk IC, Tushuizen ME, Sturk A, Dijkmans BA, Boers M, Voskuyl AE et al (2010) Circulating microparticles remain associated with complement activation despite intensive antiinflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis 69:1378 Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE et al (2013) Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 24:1849 Yin W, Ghebrehiwet B, Peerschke EIB (2008) Expression of complement components and inhibitors on platelet microparticles. Platelets 19:225 Yáñez-Mó M, Siljander PR, Andreu Z et al (2015) l.: Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. May 14;4:27066 Hargett LA, Bauer NN (2013) On the origin of microparticles: from ‘‘platelet dust’’ to mediators of intercellular communication. Pulm Circ 3:329 Cordazzo C, Neri T, Petrini S et al (2013) Angiotensin II induces the generation of procoagulant microparticles by human mononuclear cells via an angiotensin type 2 receptor-mediated pathway. Thromb Res 131:e168–e174 Preston RA, Jy W, Jimenez JJ et al (2003) Effects of severe hypertension on endothelial and platelet microparticles. Hypertens 41:211–217 Hsu CY, Huang PH, Chiang CH et al (2013) Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients. PLoS ONE 8:e68644 Huang PH, Huang SS, Chen YH et al (2010) Increased circulating CD31þ/annexin V þ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 28:1655–1665 Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M et al (2011) Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res 127:370 Witwer KW, Buzás EI, Bemis LT et al (2013) l.: Standardization of sample collection, isolation and analysis methods in extracellular vesicle research.J Extracell Vesicles. May 27;2. Young TN, Rodriguez GC, Rinehart AR et al (1996) Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62:89–99 Dolo V, D’Ascenzo S, Violini S et al (1999) Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17:131–140 VanDeun J, Mestdagh P, Sormunen R et al (2014) The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles 3:24858 Jy W, Horstman LL, Jimenez JJ et al (2004) Measuring circulating cell-derived microparticles. J Thromb Haemost 2(10):1842–1851 van der Pol E, Hoekstra AG, Sturk A et al (2010 Dec) Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost 8(12):2596–2607 Dey-Hazra E, Hertel B, Kirsch T et al (2010 Dec) Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 6:6:1125–1133 Chandler WL, Yeung W, Tait JF A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer.Journal of Thrombosis and Haemostasis, 9:1216–122 Jy W, Horstman LL, Jimenez JJ et al (2004) Measuring circulating cell-derived microparticles. J Thromb Haemost 2(10):1842–1851 Daniel L, Fakhouri F, Joly D et al (2006) Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 69(8):1416–1423 Lynch SF, Ludlam CA (2007) Plasma microparticles and vascular disorders. Br J Haematol 137(1):36–48 Erdbruegger U, Grossheim M, Hertel B et al (2008) Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford) 47(12):1820–1825 Shah MD, Bergeron AL, Dong JF, Lopez JA (2008) Flow cytometric measurement of microparticles: Pitfalls and protocol modifications. Platelets 19(5):365–372 Buschmann D, Kirchner B, Hermann S et al (2019 Mar) Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing. Extracell Vesicles 08(1):1581487 Filella M, Zhang JW, Newman ME, Buffle J (1997) Analytical applications of photon correlation spectroscopy for size distribution measurements of natural colloidal suspensions: capabilities and limitations. Colloids Surf A Physicochem Eng Asp 120:27–46 Ito T, Sun L, Henriquez RR, Crooks RM (2004) A carbon nanotube-based coulter nanoparticle counter. Acc Chem Res 37:937–945 Saleh OA, Sohn LL (2001) Quantitative sensing of nanoscale colloids using a microchip Coulter counter. Rev Sci Instrum 72:4449–4451 Joop K, Berckmans RJ, Nieuwland R et al (2001) Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 85(5):810–820 Nozaki T, Sugiyama S, Sugamura K et al (2010) Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail 12(11):1223–1228 Zhang EG, Smith SK, Charnock-Jones DS (2002 Nov) Expression of CD105 (endoglin) in arteriolar endothelial cells of human endometrium throughout the menstrual cycle. Reproduction 124(5):703–711 Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI (1994) Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Resaerch 54:2347–2358 Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE (2010) : Circulating microvesicles in B cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood; 115(9):1755–1764 Gyorgy B, Szabo TG, Turiak L et al (2012) Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases. PLoSONE 7(11):e49726 Liu R, Klich I, Ratajczak J et al (2009) Erythrocyte-derived microvesicles may transfer phosphatidylserine to the surface of nucleated cells and falsely ‘mark' them as apoptotic. Eur J Haematol 83(3):220–229 Voukalis C, Shantsilaa E, Lip GYH Microparticles, and cardiovascular diseases, ANNALS OF MEDICINE 2019, VOL. 51, NOS. 3–4, 193–223 Connor DE, Exner T, Ma DDF, Joseph JE (2010) The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 103(5):1044–1052 Boulanger CM, Amabile N, Tedgui A (2006) Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 48(2):180–186 Amabile N, Guerin AP, Leroyer A et al (2005) l.: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol ; 16(11):3381–3388 Budoni M, Fierabracci A, Luciano R et al (2013) The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transpl 22(2):369–379 Tao H, Chen X, Wei A et al (2018) l.: Comparison of Teratoma Formation between Embryonic Stem Cells and Parthenogenetic Embryonic Stem Cells by Molecular Imaging Stem Cells Int. Mar 25;2018 Ng YH et al (2013c) Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation. PLoS ONE 8:e58502 Shomali N et al (2020) Exosomes: Emerging biomarkers and targets in folliculogenesis and endometriosis. J Reprod Immunol 142:103181 Harp D, Driss A, Mehrabi S et al (2016) Exosomes derived from endometriotic stromal cells have enhanced angiogenic effects in vitro. Cell Tissue Res 365:187–196 D’Alterio MN, Saponara S, Agus M et al (2021) Medical and surgical interventions to improve the quality of life for endometriosis patients: a systematic review. Gynecol Surg 18:13 Wu C-Y, Wu J-D, Chen C-C (2021) The Association of Ovarian Teratoma and Anti-N-Methyl-D-Aspartate Receptor Encephalitis: An Updated Integrative Review. Int J Mol Sci 22:10911 The members of the Endometriosis Guideline Core Group, Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N, ESHRE Endometriosis Guideline Group (2022), Issue 2, 2022, hoac009 Tables Tables 5 and 6 are available in the Supplementary Files section. Supplementary Files Table5and6.docx Cite Share Download PDF Status: Under Review Version 1 posted Reviewers agreed at journal 11 Jul, 2022 Reviewers invited by journal 27 Jun, 2022 Editor invited by journal 26 Jun, 2022 Editor assigned by journal 05 Jun, 2022 First submitted to journal 30 May, 2022 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1707582","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":116551860,"identity":"2df3b3bd-43be-4ca3-aad7-17cd68dded24","order_by":0,"name":"Magdalena Kajdos","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABIUlEQVRIiWNgGAWjYJACCYYCEMUGZAExP4idUEBIiwGSFskGkBYDYrWAsMEBEAePFt324xdv/DCwyeNvYEv8YFFmY298fnXihwcGDPL8YgewajE7k1Ns2WOQVixxgO2whMS5tMRtN95ulgA6zHDm7ATsWg7kpEnwGBxObDjA3iAh2XY4wezG2Q0gLQkGt3FoOf8mTfKPwf/E+QfYm38Atdgbzzi7+QdeLTfSj0nzGBxI3HCA7RjIFsYN/L3b8Nty4w2ztYxBcuLGw2xpFiC/zLjBu80iwUACt1/Opz+8+abCLnHe8Tbj2xLAEOPvP7v55o8KG3l+aexaGBh4oFHADEQSIIYEWKUEDuUgwP4AzmT8ACL5D+BRPQpGwSgYBSMRAADoJmMjEu3bGAAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0002-2093-5634","institution":"Polish Mother's Memorial Hospital-Research Institute: Instytut Centrum Zdrowia Matki Polki w Lodzi","correspondingAuthor":true,"prefix":"","firstName":"Magdalena","middleName":"","lastName":"Kajdos","suffix":""},{"id":116551861,"identity":"b72c7b6e-611c-4646-b9db-6277a2b14409","order_by":1,"name":"Jacek Szymański","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Jacek","middleName":"","lastName":"Szymański","suffix":""},{"id":116551862,"identity":"d2dd0f25-b5ad-488c-b892-22beda8fc641","order_by":2,"name":"Hanna Jerczyńska","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Hanna","middleName":"","lastName":"Jerczyńska","suffix":""},{"id":116551863,"identity":"bfa3e6ab-4711-4a35-a29e-02c4958e78e7","order_by":3,"name":"Tomasz Stetkiewicz","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Tomasz","middleName":"","lastName":"Stetkiewicz","suffix":""},{"id":116551864,"identity":"c7ccc0ec-b2b1-4839-b504-8be41f5ae37e","order_by":4,"name":"Jacek Wilczyński","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Jacek","middleName":"","lastName":"Wilczyński","suffix":""}],"badges":[],"createdAt":"2022-05-30 10:48:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1707582/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1707582/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":23473228,"identity":"565784f7-475e-4698-ae1b-f1fc41c1a1ab","added_by":"auto","created_at":"2022-07-05 17:28:07","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":69918,"visible":true,"origin":"","legend":"\u003cp\u003eTwo-dimensional scatter plot \u003c/p\u003e\u003cp\u003eSSC-H side scatter height; FSC-H forward scatter height.\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/b85cb0c9a6ccf84c24e39518.jpg"},{"id":23472928,"identity":"f15d5fc9-37b4-454a-97b9-4fa4c2133b41","added_by":"auto","created_at":"2022-07-05 17:23:07","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":67841,"visible":true,"origin":"","legend":"\u003cp\u003eTwo-dimensional scatter plot\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/3f9f1ea28912fba0fedcaa14.jpg"},{"id":23473230,"identity":"1208d5f9-b649-4812-b2b4-5c92632d827a","added_by":"auto","created_at":"2022-07-05 17:28:07","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":15210,"visible":true,"origin":"","legend":"\u003cp\u003eObjects Annexin V+ in plasma in test and control group for p = 0,03.The\u003c/p\u003e\u003cp\u003eP3 K objects Annexin V positive detected in plasma in the control group,\u003c/p\u003e\u003cp\u003eP3 P objects Annexin V positive detected in plasma in the test group\u0026nbsp;\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/9b364aa8b53f93f4678f1608.png"},{"id":23472930,"identity":"55e8a290-abc2-4f94-aff5-8077f11f6102","added_by":"auto","created_at":"2022-07-05 17:23:07","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":13212,"visible":true,"origin":"","legend":"\u003cp\u003eObjects VEGF+/MMP9+ in plasma in test and control group p = 0,03\u003c/p\u003e\u003cp\u003eVEGF+/MMP9+ K objects VEGF and MMP9 positive detected in plasma in the control group,\u003c/p\u003e\u003cp\u003eVEGF+/MMP9+ P objects VEGF and MMP9 positive in plasma in the test group.\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/599ad7441fd1299e8a91c2b9.png"},{"id":23473229,"identity":"33fc00c5-da4d-4f39-882f-fbaa273d64f7","added_by":"auto","created_at":"2022-07-05 17:28:07","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":13383,"visible":true,"origin":"","legend":"\u003cp\u003eObjects MMP9+ in plasma in test and control group p = 0,02.\u003c/p\u003e\u003cp\u003eP5 K objects MMP9 positive detected in plasma in the control group,\u003c/p\u003e\u003cp\u003eP5 P objects MMP9 positive detected in plasma in the test group\u0026nbsp;\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/f587e370b5ba900518ea0e1e.png"},{"id":23472933,"identity":"36842d7c-a786-4056-9f29-ce3c3b200667","added_by":"auto","created_at":"2022-07-05 17:23:07","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":7163,"visible":true,"origin":"","legend":"\u003cp\u003eDouble-positive VEGF (+) / MMP9 (+) objects in test and control groups. \u003c/p\u003e\u003cp\u003e \u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/a781cff9aad3925b9eab888a.png"},{"id":23473231,"identity":"eec52c9d-83af-4fac-ab9e-c75730f09606","added_by":"auto","created_at":"2022-07-05 17:28:10","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":565695,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/22bc34c3-e579-4ac4-8110-596d94aab70a.pdf"},{"id":23472934,"identity":"811518f6-c219-4c2d-8230-9eddc4e5cd75","added_by":"auto","created_at":"2022-07-05 17:23:08","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":375648,"visible":true,"origin":"","legend":"","description":"","filename":"Table5and6.docx","url":"https://assets-eu.researchsquare.com/files/rs-1707582/v1/8fe1a0c5651a2939aa816575.docx"}],"financialInterests":"","formattedTitle":"Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eEndometriosis is a common gynecological disorder defined by the proliferation of endometrial glands and stroma outside the normal uterine cavity [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. It affects especially women of reproductive age, but girls before menarche and postmenopausal women are occasionally diagnosed as well [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. 20\u0026ndash;50% infertile women suffer from endometriosis [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The physical, mental and social well\u0026ndash;being is reduced significantly.\u003c/p\u003e \u003cp\u003eClinical manifestation of endometriosis is not characteristic. The disease can be asymptomatic; however, permanent or temporary pain is common. Dysmenorrhea, dyspareunia, and infertility are the typical and common triad of endometriosis symptoms [\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e]. The symptoms also depend on the localization of ectopic endometrial lesions. Endometrial implants in the peritoneum of recto-uterine and vesicouterine excavation, Sacro-uterine ligaments, and rectovaginal septum cause pain and bleeding during urination and defecation, pain in the sacral spine, and pain radiating to the thighs. However, ovaries, fallopian tubes, and pelvic and abdominal peritoneum are more common localization for endometrial implants. Chocolate cysts filled with hemolyzed blood are a typical sign of ovarian endometriosis. Endometrial glands and stroma can grow into the myometrium layer and lead to uterine muscle tissue changes called adenomyosis. Extra pelvic endometriosis is rare and occurs in well-vascularized organs, for example, the intestine, lung, or brain [\u003cspan additionalcitationids=\"CR4\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe pathogenesis of endometriosis remains unclear. Many theories explain how endometrial implants form, but neither describes this process clearly. Retrograde menstruation is accepted as the most plausible sequence of events leading to lesions establishment [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] According to the new hypothesis, endometriosis could also originate from endometrial stem cells or mesenchymal stem cells from the bone marrow homing peritoneal cavity and differentiating into endometrial cells. The viable endometrial cells spread and attach to the peritoneal surface. The success of the ectopic implants depends on the inflammatory response, neoangiogenesis, fibrosis, adhesion formation, avoidance of apoptosis, immune dysfunction of the host, and neuronal infiltration [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan additionalcitationids=\"CR10 CR11 CR12\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The exact pathological mechanisms are observed both in endometriosis and neoplastic disease. Angiogenesis is one of the critical steps engaged in those pathologies.\u003c/p\u003e \u003cdiv id=\"Sec2\" class=\"Section2\"\u003e \u003ch2\u003e1.1. Role of angiogenesis in endometriosis pathogenesis\u003c/h2\u003e \u003cp\u003eAngiogenesis is a multistep process of forming new blood vessels and occurs both in physiological and pathological conditions. The new blood vessels form by budding endothelial cells into the extracellular matrix, which is strictly regulated. Endothelial cells and other cells (e.g., macrophages, neoplastic cells) release growth factors characterize for angiogenesis (VEGF, bFGF) to degrade the existing vessel\u0026rsquo;s wall. VEGF (\u003cem\u003evascular endothelial growth factor\u003c/em\u003e) is the main proangiogenic factor. It influences endothelial cells\u0026rsquo; proliferation, migration, and apoptosis. Activated endothelial cells release proteolytic enzymes to degrade the base membrane allowing more effortless movement of cells. Metalloproteinases (enzymes modeling matrix) cause changes in the composition of the base membrane. Metalloproteinases modify the extracellular matrix to promote the migration of epithelial cells and the process of neovascularization [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Cells combine to form capillary buds. A synthesis of base membrane components and the development of the other layers of the vessel produces further stabilization of the vessel.\u003c/p\u003e \u003cp\u003eThe web of blood vessels surrounding endometriosis foci is characteristic of this disease and confirmed in microscopic studies [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Cells of ectopic endometrium, immune cells, and mesothelium cells release the growth factors and proteolytic enzymes into the peritoneal cavity. Macrophages and mast cells from peritoneal fluid and endometriosis foci are the primary sources of VEGF [\u003cspan additionalcitationids=\"CR17 CR18\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Increased concentration of the soluble form of VEGF was observed in peritoneal fluid collected from patients with advanced endometriosis [1,218,20\u0026ndash;22]. Some studies also demonstrated the highest concentration of VEGF in endometrial cysts and red implants [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The expression of VEGF, VEGF-2, and the number of activated macrophages correlates to the expression of metalloproteinase 9 in both peritoneal fluid and endometrial implants [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Moreover increased amount of metalloproteinases MMP-2, MMP-3, MMP-7, and MMP-9 is observed in patients with endometriosis [\u003cspan additionalcitationids=\"CR26\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. This fact confirms enhanced proteolysis in ectopic endometrium [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e1.2. \u003cb\u003eRole of peritoneal fluid in endometriosis pathogenesis\u003c/b\u003e\u003c/h2\u003e \u003cp\u003ePeritoneal fluid is the most critical factor controlling the peritoneal cavity microenvironment and is observed in physiological and pathological conditions. Physiologically, peritoneal fluid ranges from 5 to 20 ml in size, and the amount depends on the menstrual cycle phase. Its production increases in endometriosis and infertility [\u003cspan additionalcitationids=\"CR29 CR30\" citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. The fluid arises through plasma filtration, the ovaries secretion, tubal mucus production, retrograde menstruation, and macrophages activity to produce and secrete proinflammatory cytokines/chemokines. It contains cells elements (macrophages, natural killers cells, lymphocytes, eosinophils, mast cells, and mesothelial cells) and substances they produce (cytokines, prostaglandins, hydrolytic enzymes, complement components, and oxygen free radicals) [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eChanges in the composition of peritoneal fluid in endometriosis result from immune responses and their direct contact with the endometrial implants. Chronic inflammation in the pelvic cavity is a consequence of humoral and cell-mediated responses. The concentration of T cells increases, followed by the increase of the T-helper / T-suppressor ratio[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. The number of NK cells responsible for removing ectopic endometrial cells increases. However, they are dysfunctional and fail to kill ectopic implants [\u003cspan additionalcitationids=\"CR33 CR34 CR35\" citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. A significant rise in macrophages is observed, and the cells demonstrate higher activin than macrophages from healthy women [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Macrophages and cells of endometrial implants produce the following cytokines: IL-8, IL-10, ICAM-1, MCP-1, RANTES, VEGF, IGF, EGF, M-CSF, HGF, which are found in higher concentrations in the peritoneal fluid [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. This fact confirms the existence of subclinical inflammation inside the peritoneal cavity. Immunological and angiogenic factors present in the pelvic environment participate in the pathogenesis of endometriosis [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e1.3. \u003cb\u003eMicrovesicles\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eExtracellular vesicles were described in 1967 by Wolf [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e] as waste products of the human body. Further studies showed that cells could release more different vesicles and apoptotic bodies, exosomes, and microvesicles (MVs). Microvesicles have different shapes ranging from 100 to 1,000 nm in size [\u003cspan additionalcitationids=\"CR38\" citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. The shape and size depend on MVs\u0026rsquo; origin and function. Regulated release from outward budding or blebbing on the plasma membrane [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] causes the formation of the MVs. Health cells shed MVs from selected areas, whereas tumor cells from the entire surface [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Specific markers for MVs have not been identified yet. Previous research has used selectins, integrins, flotillin-2, CD-40, and metalloproteinase [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. The release of MVs was confirmed in normal cells types, including red blood cells, platelets, endothelial cells, and pathological mostly cancer cells [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan additionalcitationids=\"CR44\" citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eMicrovesicles can transport enzymes, regulatory and growth factors, cytokines, lipids, and nucleic acid (mRNA, miRNA, ncRNA, genomic DNA) [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan additionalcitationids=\"CR47 CR48 CR49\" citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. They are responsible for homeostasis in human organisms and the induction of pathological processes. Proteolytic enzymes and proangiogenic factors play a role in creating new vessels. They are the MVs\u0026rsquo; cargo, as confirmed in cancer, and could in similar promote and regulate the creation of new endometrial implants. Moreover, MVs with regulatory factors could theoretically induce the tolerance against foci of ectopic endometrium and mediate angiogenesis. That was the assumption leading to the start of the study.\u003c/p\u003e \u003c/div\u003e"},{"header":"2. Objectives","content":"\u003cp\u003eTime from first symptoms to the final diagnosis of endometriosis is essential. Nowadays, it takes from 7 to 11 years [\u003cspan additionalcitationids=\"CR52 CR53\" citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. Diagnosis is based on clinical signs; however, surgery and histological examination are the strongest confirmation Clinicians are recommended to use imaging (US or MRI) in the diagnostic work-up for endometriosis, but they need to be aware that a negative finding does not exclude endometriosis, particularly superficial peritoneal disease [\u003cspan citationid=\"CR108\" class=\"CitationRef\"\u003e108\u003c/span\u003e]. It explains why new diagnostic tools are needed.\u003c/p\u003e \u003cp\u003eBlood markers have not been found yet. Our study was conducted to find microvesicles in peripheral blood and peritoneal fluid collected from women with benign ovarian lesions like ovarian endometrioma or teratoma. Teratoma is a germ cells tumor that differentiates toward somatic-type cell populations [\u003cspan citationid=\"CR107\" class=\"CitationRef\"\u003e107\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIf the presence of MVs is confirmed, we decided to investigate if they were filled with essential angiogenesis mediators, like vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9). Previous research revealed a higher VEGF in peritoneal fluid and foci of ectopic endometrium [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. The same observation concerned metalloproteinases 9 and 2 [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. In addition, the correlation between MMP-9 and VEGF in endometriosis foci was found [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. However, the transport of VEGF and MMP-9 in MVs has never been studied both in endometriosis and teratoma.\u003c/p\u003e"},{"header":"3. Materials And Methods","content":"\u003cp\u003eThe study was conducted in Dept. of Gynecology and Gynecologic Oncology PMHCRI from 2014 to 2017 based on two grants (NCN UMO-2014/13/D/N/Z5/00446 \u0026ndash; \u0026ldquo;Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis\u0026rdquo;; Young Researcher PMHCRI Grant \u0026ndash; \u0026ldquo;Microvesicles as a potential biomarker of endometriosis\u0026rdquo;). The isolation technique was tested and finally established during the preliminary phase of the study provided by Young Researcher Grant. The Ethical Commission of the Polish Mother Memorial Hospital Research Institute approved all studies (decision number 40/2013).\u003c/p\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e3.1. \u003cb\u003ePatients\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eThe patients operated on for benign lesions of ovaries in PMHCRI were qualified for the study. All patients were given information about endometriosis and signed informed consent. Forty-seven women aged 20\u0026ndash;60 took part in the study. Women operated on for endometriosis were the test group, whereas women with teratoma formed the control group. Moreover, patients with chronic diseases such as cardiac problems (blood hypertension, ischemic heart disease), thyroid diseases, and autoimmune diseases (Hashimoto\u0026rsquo;s disease, psoriasis, atopic dermatitis, lupus, Crohn\u0026rsquo;s disease, celiac disease) were excluded from the research due to the observations that MVs could be present and play a role in the pathogenesis of these diseases.\u003c/p\u003e \u003cp\u003eClinical presentation and ultrasound examination determined patients\u0026rsquo; qualifications for to test or control group. The ovarian lesions were firstly examined using ultrasound performed by a doctor having great experience in ultrasonography. The doctor performed gynecological ultrasounds in PMHCRI for many years. During this time he saw different cases of endometriosis and other gynecological diseases. That gives him the qualification to diagnose even small endometrial lesions, difficult to see for others. However, the diagnosis was confirmed during operation and finally in histopathological examination.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e3.2. \u003cb\u003eSamples\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eMicrovesicles (MVs) were determined in samples of 5 ml blood and samples of 5 ml peritoneal fluid. The blood samples were collected upon admission while taking the blood sample for preoperative test. The fluid was collected from the peritoneal cavity during the g operation. Blood and peritoneal fluid samples were dispensed into tubes containing trisodium citrate solution serving as an anticoagulant. Blood samples were collected through a 16 gauge needle (S-Monovette\u0026reg;-Needle) into a syringe (S-Monovette\u0026reg; 5ml, Citrate 3.2% (0.106mol/l)). Peritoneal fluid samples were collected at the beginning of operations. Fluid from the Douglas pouch was collected through a laparoscopic needle into a sterilized syringe. It was done after abdominal cavity insufflation when a camera and trocars were put through the abdominal wall. Fluid from the sterilized syringe was put into a blood collecting tube with 3.2% Na Citrate (5ml volume). Samples of peritoneal fluid were not collected from all patients undergoing operations because either the fluid was not found or its amount was too small to collect.\u003c/p\u003e \u003cp\u003eThirty samples of plasma and 27 samples of peritoneal fluid were collected. Plasma samples were collected from 23 patients with endometriosis (test group) and seven patients with teratoma (control group); twenty-seven peritoneal fluid samples were collected: 19 in the test group and 8 in the control group. Both peritoneal fluid and plasma were collected from 10 patients (7 in the test group and 3 in the control group). Table\u0026nbsp;1 presents the distribution of patients the in test and control group.\u003c/p\u003e\u003cp\u003e\u003cb\u003eTable\u0026nbsp;1.\u003c/b\u003e Distribution of patients in test and control groups. (Table is explained in the text above)\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"No\" id=\"Taba\" border=\"1\"\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eAll patients\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePFP\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePeritoneal fluid\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePFP and peritoneal fluid\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTest group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eControl group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBoth group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003ePFP \u0026ndash; platelet free plasma\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.3. \u003cb\u003eMVs isolation and samples storage\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eSamples of blood and peritoneal fluid have undergone the process of getting platelet-free plasma (PFP)/platelet-free peritoneal fluid. The method was developed in the Central Research Laboratory (CoreLab) of Medical University in Lodz and is based on previously published studies [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e, \u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e]. The first stage was performed in PMHCRI. The samples underwent centrifugation to remove platelets, erythrocytes, and other large fragments, which could interfere with subsequent analysis. The platelet free plasma (PFP) was prepared from a solution of anticoagulant and blood through singular centrifugation at 3000xg for 15 minutes in angle\u0026ndash;headed rotor. The centrifugation to isolate MVs was performed in less than thirty minutes after blood and peritoneal fluid collection. PFP was collected from sediment and stored in special tubes for freezing. Samples of peritoneal fluid with anticoagulants have undergone the same process of centrifugation. Supernatant formed during centrifugation was collected as platelet-free peritoneal fluid. It was stored in tubes fit to freeze at minus 40\u003csup\u003eo\u003c/sup\u003e Celsius. All samples (PFP/platelet free peritoneal fluid) were frozen at minus 40\u003csup\u003eo\u003c/sup\u003e Celsius after centrifugation and stored for subsequent analysis.\u003c/p\u003e \u003cp\u003eThe second stage of MV\u0026rsquo;s isolation was performed in the Central Research Laboratory of Medical University in Lodz. Frozen samples of PFP and platelet-free peritoneal fluid were transported in an icebox to protect them from thaw and put at the same temperature (-40℃). Frozen aliquots (2ml) were thawed at ambient temperature for 20\u0026ndash;30 minutes and mixed well but delicately to limit the possible extent of \u003cem\u003ein vitro\u003c/em\u003e MVs generation. Different times and speeds were tested to choose the optimal conditions. Data was not shown, due to the large number of them. Moreover, their presentation will not improve the value of our publication. Optimal conditions did not cause substantial loss of MVs but let pellet bigger debris. From each sample, portions of 2 x 650\u0026micro;l were taken and centrifuged at 1000 x g for 5 minutes in a commonly used tabletop centrifuge (Eppendorf). To prepare the sample for further processing, 500\u0026micro;l of supernatant was taken from each portion, then combined and mixed gently in one Eppendorf tube. As the next step, 100 \u0026micro;l aliquots of isolated MVs were used.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e3.4. \u003cb\u003eAntibodies and Incubation\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eThe study used six types of antibodies. Annexin V was chosen as a substance commonly used to stain MVs in previous research. One of the study assumptions was finding MVs revealed from ectopic endometrium cells (endometriosis focus). Antibodies for CD105, CD146, and cytokeratin (CK 18) were used to confirm this thesis. Those structures were found on the endometrial cell surface. Antibodies for VEGF and MMP-9 were the last group. Their presence inside microvesicles could confirm MVs\u0026rsquo; role in angiogenesis \u0026ndash; one of the main processes observed in endometriosis development.\u003c/p\u003e \u003cp\u003eAliquots of microvesicles (100 \u0026micro;l) were incubated at room temperature with proper antibodies for 25\u0026ndash;30 minutes, protected from light. Three sets of antibodies mixtures were prepared:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eSet 1: Annexin V (5\u0026micro;l\u0026thinsp;+\u0026thinsp;13\u0026micro;l buffer), CK 18 (10\u0026micro;l), MMP \u0026ndash; 9 (2 \u0026micro;l) and VEGF (10 \u0026micro;l)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eSet 2: Annexin V (5\u0026micro;l\u0026thinsp;+\u0026thinsp;13\u0026micro;l buffer), CD 105 (10\u0026micro;l), MMP \u0026ndash; 9 (2 \u0026micro;l) and VEGF (10 \u0026micro;l)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eSet 3: Annexin V (5\u0026micro;l\u0026thinsp;+\u0026thinsp;13\u0026micro;l buffer), CD 146 (10\u0026micro;l), MMP \u0026ndash; 9 (2 \u0026micro;l) and VEGF (10 \u0026micro;l)\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eStained samples were analyzed after setting the correct conditions.\u003c/p\u003e \u003cp\u003eThree sets of four monoclonal antibodies were created to reduce possible interference. The sets (set 1, set 2, set 3) differed in the molecule found on the surface of endometrial cells (CK18, CD105, CD146, respectively) [Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e2\u003c/span\u003e]. Objects with a different arrangement of monoclonal antibodies were counted in each set [Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e3\u003c/span\u003e]. Moreover, objects positively for single monoclonal antibodies were counted.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSets of four monoclonal antibodies\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSet 1\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCK 18\u0026thinsp;+\u0026thinsp;AnnexinV\u0026thinsp;+\u0026thinsp;VEGF\u0026thinsp;+\u0026thinsp;MMP-9\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSet 2\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eCD 105\u0026thinsp;+\u0026thinsp;AnnexinV\u0026thinsp;+\u0026thinsp;VEGF\u0026thinsp;+\u0026thinsp;MMP-9\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSet 3\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eCD 146\u0026thinsp;+\u0026thinsp;AnnexinV\u0026thinsp;+\u0026thinsp;VEGF\u0026thinsp;+\u0026thinsp;MMP-9\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"2\"\u003eCK 18 \u0026ndash; cytokeratin 18, VEGF - Vascular Endothelial Growth Factor, MMP-9 \u0026ndash; metalloproteinase 9\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDifferent confirmation of monoclonal antibodies in set 1, set 2, set 3\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSet 1\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSet 2\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSet 3\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVEGF+/MMP9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eVEGF+/MMP9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eVEGF+/MMP9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAll+(AnnexinV+/CK18+)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eAll +\u0026thinsp;1(AnnexinV+/CD105+)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eAll+-1(AnnexinV+/CD146+)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAnnexinV+/MMP9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eAnnexinV+/MMP9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eAnnexinV+/MMP9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAllq+(VEGF+/CK18+)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eAllq+-1(VEGF+/CD105+)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eAllq+-1(VEGF+/CD146+)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAnnexinV+/CK18+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eAnnexinV+/CD105+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eAnnexinV+/CD146+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVEGF+/CK18+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eVEGF+/CD105\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eVEGF+/CD146\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCK18+/MMP-9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eCD105+/MMP-9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eCD146+/MMP-9+\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"3\"\u003eCK 18 \u0026ndash; cytokeratin 18, VEGF - Vascular Endothelial Growth Factor, MMP-9 \u0026ndash; metalloproteinase 9\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e3.5. \u003cb\u003eFlow Cytometry\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eFACSCanto II Biosciences cytometer was used to analyze MVs in peripheral blood and peritoneal fluid collected from women with benign ovarian lesions (endometriosis and teratomas). Proper gating was set up for structures as small as MVs. Specialized beads were used to achieve it (Megamix \u0026ndash; SSC Biocytex). They had a similar size to microvesicles. Their size was ranging from 0.1 \u0026micro;m to 1 \u0026micro;m. MVs stained by monoclonal antibodies were analyzed after setting the correct gate. The obtained data were quantified and plotted using the BD FACSDiva software (Becton Dickinson). Data on events ranging in size from 0.22 \u0026micro;m to 0.24 \u0026micro;m (220\u0026ndash;240 nm) were analyzed statistically. The obtained data were quantified and plotted. An example of a two-dimensional scatter plot is presented below (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e and Fig.\u0026nbsp;2), and the explanation is in Table number 4.\u003c/p\u003e\u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eExplanation of two-dimensional scatters plot.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAll\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRectangle with yellow frame shows all events detected by flow cytometry\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e05\u0026thinsp;\u0026minus;\u0026thinsp;1/024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRectangle with blue frame shows events in size bigger than 0.24 \u0026micro;m (240nm)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e05\u0026thinsp;\u0026minus;\u0026thinsp;1/02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRectangle with red frame shows events in size from 0.20 \u0026micro;m (200 nm)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e3.5. \u003cb\u003eStatistical analysis\u003c/b\u003e\u003c/h2\u003e \u003cp\u003eSTATISTICA was used to analyze obtained results. Median, 1st, and 3rd quartiles were counted for each type of mark in individual sets (set 1, set 2, set 3) and in each subgroup of patients. Median gave the average value in patients groups, whereas 1st and 3rd quartiles measured the scatter of results. Mann\u0026ndash;Whitney\u0026rsquo;s test was used to compare both groups of patients. The null hypothesis was that analyzed data were from the same population or population with identical medians. p Values lower than 0.05 allowed to reject the null hypothesis with a significance level of 0.05 and accept the alternative theory that the medians in the groups are different.\u003c/p\u003e \u003cp\u003eMoreover, the correlation of MVs amount in plasma and peritoneal fluid was checked. The clustering of patients within groups (plasma and peritoneal fluid) was performed to show the cytometry results between groups. Logistic regression was used to predict from MVs profile whether the patient was in the test or control group.\u003c/p\u003e \u003c/div\u003e"},{"header":"4. Results","content":"\u003cp\u003eCytometry analysis confirmed MVs\u0026rsquo; presence in plasma and peritoneal fluid collected from patients with endometriosis and teratomas. A statistically significant higher level of AnnexinV (+) MVs were observed in plasma samples of endometriosis patients (Fig.\u0026nbsp;3). In the teratoma group, there was a significant percentage of double-positive VEGF (+) / MMP9 (+) (Fig.\u0026nbsp;4) and single MMP9 (+) positive MVs in the serum (Fig.\u0026nbsp;5). The error bars, in Figs.\u0026nbsp;3 to 5, shoved standard deviation. Moreover, the above differences are summarized in Table\u0026nbsp;5.\u003c/p\u003e\n\u003cdiv\u003eIn the peritoneal fluid higher frequency of double-positive VEGF (+), / MMP9 (+) MVs were found in the control group. However, the amount of VEGF (+) / MMP9 (+) MVs object did not differentiate between the test and control groups (Fig.\u0026nbsp;6). The above differences are summarized in Table\u0026nbsp;6.\u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eThe study was the first in which MVs were confirmed in plasma and peritoneal fluid in benign conditions like endometriosis and teratoma. Different MVs are found in both physiological conditions and healthy bodies and diseases [\u003cspan additionalcitationids=\"CR58 CR59\" citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. Studies in which MVs have been analyzed in gynecological disorders are not common. Researchers focused mostly on MVs present in ascites that accompany ovarian cancer, not on the MVs population in the benign lesions.\u003c/p\u003e \u003cp\u003eIt is worth mentioning that the study group was the biggest group of patients with gynecological diseases, in which MVs were studied. Despite the fact, that the strict exclusion criteria influenced negatively the study participants numbers. Ten patients were excluded because of abnormal levels of thyroid gland hormones. Further tests confirmed hypothyroidism or Hashimoto\u0026rsquo;s disease. MVs increase is observed in autoimmunological diseases [\u003cspan additionalcitationids=\"CR62\" citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e], kidney disorders [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e], and vascular diseases [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. MVs take part in immunological response through antigens transport and presentation [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e]. Microvesicles are also described as proinflammation mediators [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e]. Based on those facts, patients with endocrine disorders and infections were not qualified for the study. Microvesicles are also observed in cardiological problems, such as hypertension or atherosclerosis disease. MVs with procoagulant features are released from monocytes and can induce a formation of an atherosclerotic plaque [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e, \u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e, \u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e]. MVs have influenced deterioration of the renal function in patients with hypertension [\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e, \u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e, \u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWe hoped to collect peritoneal fluid from every operated patient, but the peritoneal fluid was not found in every case. This fact made it impossible to check correlations between MVs numbers in peritoneal fluid and peripheral blood. Moreover, peritoneal fluid contaminated by blood or chocolate cysts could not be used.\u003c/p\u003e \u003cp\u003eFirst centrifugation of blood and peritoneal fluid samples was performed within 30 minutes from samples collection. Time range was vital because we wanted to analyze MVs presented in blood and peritoneal fluid at the moment of collection. Prior studies showed that MVs are released from activated cells \u003cem\u003ein vitro\u003c/em\u003e [\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e]. Moreover, the correlation between MVs amount and time from collection of blood samples was observed [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e]. The same assumption was made for the collection of peritoneal fluid samples. Microvesicles were not analyzed in peritoneal fluid in non-oncological diseases previously. Studies were performed on specimens collected from patients with ascites. The composition of ascites fluid differs from the peritoneal fluid. The differences are shown in cells, proteins, macro, and microelements [\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e, \u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e]. Moreover, the peritoneal fluid composition is different from blood. It contains cells not observed in the blood, such as endometrial cells, adipocytes, and mesothelial cells.\u003c/p\u003e \u003cp\u003eThe centrifugated samples were frozen to minus 40℃, which allowed safe storage and transport. Witwer et al. froze FPF at minus 80℃, but Jayachandran et al. revealed that freezing in higher temperatures did not influence MVs composition and amount [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e, \u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e]. Moreover, the negative effect of dehydration was avoided [\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eChoice of isolation method was not easy because methods of MVs isolation are not united and standardized [\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e, \u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e]. Many researchers tried different times and speeds of centrifugation to get the optimal amount of microvesicles. Utracentrifuges were also used; however, they led to a new MVs generation. We wanted to avoid that. We followed the methodology described by the papers in which MVs released from platelets, leukocytes, and epithelial cells were analyzed [\u003cspan additionalcitationids=\"CR80 CR81 CR82 CR83 CR84\" citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBased on them, we decided to reduce the number of centrifugation after samples defrosting. More than one centrifugation did not give a statistically significant difference in MVs amount [\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e]. Moreover, the speed was reduced, resulting in more MVs [\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e]. Shah MD et al. also showed more MVs originated from epithelial cells when they used a shorter time of centrifugation [\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn prior studies, optical and non-optical methods were used to analyze small subjects like microvesicles. More research was conducted with flow cytometry than with TEM (transmission electron microscope) and AFM (atomic force microscope). Despite TEM and AFM having higher resolution, the process of MVs isolation is more complicated and requires a restrictive condition of samples preparation [\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e]. In flow cytometry, it is possible to measure the intensity of scattered light and fluorescence of a singular subject in a hydrodynamically focused fluid stream [\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e]. In addition, the results of flow cytometry analysis are repeatable and plausible [\u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe release of MVs from endothelium and epithelium cells was confirmed previously [\u003cspan additionalcitationids=\"CR58 CR59\" citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. Based on those facts, we assumed that endometrium had adequate abilities. MVs were stained by monoclonal antibodies for cytokeratin 18, CD 105, and CD 146, typical markers for endometrial cells. Bokor et al. analyzed the cells composition of peritoneal fluid collected from women with endometriosis. They revealed cells with cytokeratins 18, 19, and vimentin in PF [\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e] which explained retrograded menstruation as a cause of endometriosis. Linden et al. also analyzed peritoneal fluid composition in endometriosis. They found endometrial cells positive for CK 18 in both groups of patients, one with endometriosis and the other without [\u003cspan citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e]. In this research, we observed more subjects with CK18 positive in PF in both groups of patients.\u003c/p\u003e \u003cp\u003eAntibodies characteristic of endometrium were chosen to mark MVs in peritoneal fluid and blood samples. The choice was made based on previous studies. Zhang et al. observed the increase of CD105 on endothelial cells in small vessels in the endometrium [\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e]. Moreover, the expression of CD105 and CD146 was observed in the endometrium and its stroma [\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e, \u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e]. Annexin V was widely used as a marker for microvesicles released from most types of cells in the human body [\u003cspan additionalcitationids=\"CR95\" citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR96\" class=\"CitationRef\"\u003e96\u003c/span\u003e]. This research suggests the presence of MVs annexin V positive but not in all sets. The absence of MVs annexin V positive is surprising and it might suggest that not all MVs contain phosphatidylserine [\u003cspan additionalcitationids=\"CR99 CR100\" citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eEndometriosis development depends on a web of new vessels. Endothelial cells are stimulated by growth factors to proliferation, whereas enzymes change the extrauterine matrix to make more space for new vessels. Endometrium epithelium cells can release vesicles, which transfer molecules to the endometrium, also the ectopic one too [\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e]. Harper et. al isolated microvesicles in samples of endometrium collected from healthy individuals and patients with endometriosis [\u003cspan citationid=\"CR105\" class=\"CitationRef\"\u003e105\u003c/span\u003e]. VEGF and MMP-9 as angiogenesis markers should be observed in MVs analyzed in FPF and PF collected in the test group. However, MVs stained antibodies for VEGF and MMP-9 were found in set 3 in both media collected in the control group. Moreover, more MVs with single antibodies for MMP-9 were found in the same group of patients. It could indicate intensive angiogenesis in benign ovarian lesions such as teratomas. Tao et al. had similar results in their study of the VEGF/VEGFR2 trail of angiogenesis [\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e]. Several studies focused on miRNAs enabled to regulate angiogenesis. The regulation is based on the influence on VEGF-A production [\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e]. Higher expression of miR16\u0026thinsp;\u0026minus;\u0026thinsp;5p, miR-138, miR-29c-3p, and miR-424\u0026thinsp;\u0026minus;\u0026thinsp;5p was shown in endometriosis [\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e]\u003c/p\u003e \u003cp\u003e The strength of the study is the strict exclusion criteria and the methodology based both on the literature and personal testing of different conditions to optimize the MVs harvest. The weakness is the fact that based on the results it was not possible to bring patients under the category of endometriosis or teratoma. Even though the groups have been the greatest studied so far, it occurs that they could be too small to show properly the differences between the groups based on the peritoneal fluid samples.\u003c/p\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003eMicrovesicles are present in peripheral blood and peritoneal fluid samples collected from patients with endometriosis and teratoma.\u003c/p\u003e \u003cp\u003eMicrovesicles with proangiogenic factors (VEGF and MMP-9) are more commonly observed in blood and peritoneal fluid samples from patients with teratoma.\u003c/p\u003e"},{"header":"Declarations","content":" \u003cp\u003e \u003cstrong\u003eAuthor Contributions\u003c/strong\u003e \u003cp\u003e All authors have read and agreed to the published version of the manuscript\u003c/p\u003e \u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest:\u003c/strong\u003e \u0026ldquo;The authors declare no conflict of interest\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGiusti I, D'Ascenzo S, Dolo V (2013) Microvesicles as Potential Ovarian Cancer Biomarkers, Biomed Res Int. ; 2013:703048\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ (2001) Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types Int. J Gynecol Pathol 20:133139\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHadfield RM, Mardon HJ, Barlow DH, Kennedy SH (1997) : Endometriosis in monozygotic twins; Fertil Steril. Nov;68(5):941-2\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLauchlan SC (1972) The secondary M\u0026uuml;llerian system. Obstet Gynecol Surv 27:133\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eInal JM et al (2013) Blood/plasma secretome and microvesicles,Biochim. Biophys. Acta\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeckes DG Jr, Raab-Traub N (2011 Dec) Microvesicles and viral infection. J Virol 85(24):12844\u0026ndash;12854\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, Araoz PA, Budoff MJ, Harman SM, Miller VM (2008 Sep) Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 295(3):H931\u0026ndash;H938\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD'Souza-Schorey C, Clancy JW Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.Genes Dev. 2012 Jun15;26(12):1287\u0026ndash;99\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFrey GH, Bluefield WV (1957) The familial occurrence of endometriosis. Am J Obstet Gynecol 73:418\u0026ndash;422\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGardiner L Endometriosis. Obstet Gynecol 1953, 1, 615\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRanney B, Endometriosis IV (1971) Hereditary tendency. Obstet Gynecol 37:734\u0026ndash;737\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePractise Committee of American Society for Reproductive Medicine (2006) Endometr infertility Fertil Steril 86:S156\u0026ndash;160\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBulun SE, Endometriosis (2009) N Engl J Med 360:268279\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu Z, Mamillapalli R, Taylor HS (2019) Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis. Am J Physiol Endocrinol Metab 316:E373\u0026ndash;E382\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSaha R, Pettersson HJ, Svedberg P, Olovsson M, Bergqvist A, Marions L, Tornvall P, Kuja-Halkola R (2015 Oct) :.Heritability of endometriosis, Fertil Steril. 104:947\u0026ndash;9524\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilczyński JR, Szyłło S (2013)K., Elsevier Urban \u0026amp; Partner, Wrocław. ;:47\u0026ndash;55\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKyama CM, Debrock S, Mwenda JM, D\u0026rsquo;Hooghe TM (2003) Potential involvement of the immune system in the development of endometriosis. Reproad Biol Endocrinol 1:123\u0026ndash;132\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcLaren J, Prentice A, Charnock-Jones DS et al (1996) Vascular Endothelial Growth Factor Is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroides. J Clin Invest 98:482\u0026ndash;489\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTariverdian N, Theoharides TC, Siedentopf F et al Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach.Semin Immunopathol207, 29,193\u0026ndash;210\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGargett CE, Masuda H (2010) Adult stem cells in the endometrium. Molec Hum Reprod 16(11):818\u0026ndash;834\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShifren JL, Tseng JF, Zaloudek CJ et al (1996) Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J of Clinl Endocrin and Metabol 81(8):3112\u0026ndash;3118\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMueller MD, Lebovic DI, Garrett E, Taylor RN (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 74(1):107\u0026ndash;112\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMerrill JA (1966) Endometrial induction of endometriosis across Millipore filters. AmJObstetGynecol 94:780\u0026ndash;790\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAntoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:5898\u0026ndash;5905\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRadowicki S, Szyłło K (2013) : Endometrioza, diagnostyka i leczenia, (2), 6\u0026ndash;18\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eForehand JR, Johnston RB, Bomalski JS (1993) Phospholipase A2 activity in human neutrophils. J Immunol 151:4918\u0026ndash;4925\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGarcie-Velasco JA, Arici A (1999) interleukin-8 stimulates the adhesion of endometrial stroma cells to fibronectin. Fertil Steril 72:336\u0026ndash;340\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKoninckx PR, Kennedy SH, Barlow DH (1999) Pathogenesis of endometriosis: the role of peritoneal fluid. Gynecol Obstet Invest 47:23\u0026ndash;33\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaathuis JB, Van Pf L, Michie EA (1978) Changes in volume, total protein and ovarian steroid concentration of peritoneal fluid throughout the human menstrual cycle. J Endocrinol 76:123\u0026ndash;133\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSyrop CH, Halme J (1987) Peritoneal fluid environment and infertility. Fertil Steril 48:1\u0026ndash;9\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePolak G, Kotarski J (2013) The role of peritoneal fluid in pathogenesis of endometriosis,Endometriosis. Diagnosis and Treatment1\u0026ndash;5\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan der Linden PJ (1996) Theories on the pathogenesis of endometriosis. Hum Reprod Oxf Engl 11(Suppl 3):53\u0026ndash;65\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTaylor RN, Yu J, Torres PB et al (2009) Mechanistic and Therapeutic Implication of Angiogenesis in Endometriosis. Reprod Sci1 16:140\u0026ndash;146\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLagan\u0026agrave; AS, Garzon S, G\u0026ouml;tte M, Vigan\u0026ograve; P, Franchi M, Ghezzi F, Martin DC (2019) The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights. Int J Mol Sci 20:5615\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWaldeyer H \u0026ldquo;Die epithelialen Eierstockgeschw\u0026uuml;lste.\u0026rdquo; Ins besonders die Kystome: The epithelial ovarian tumors, especially the cystic tumors).Arch Gyn\u0026auml;kol1870, 1,252\u0026ndash;316\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMiyazaki K, Dyson MT, Coon V, Furukawa JS, Yilmaz Y, Maruyama BD, Bulun T (2018) Generation of Progesterone-Responsive Endometrial Stromal Fibroblasts from Human Induced Pluripotent Stem Cells: Role of the WNT/CTNNB1 Pathway. Stem Cell Rep 11:1136\u0026ndash;1155\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoen MH, Magnus P (1993) The familial risk of endometriosis. Acta Obstet Gynecol Scand 72:560\u0026ndash;564\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimpson JL, Elias S, Malinak LR, Buttram VC (1980) Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 137:327\u0026ndash;331\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaliniak LR, ButtramVC, Elias S, Simpson JL (1980) Heritable aspects of endometriosis. II. Clinical characteristics of familial endometriosis. Am J Obstet Gynecol 137:332\u0026ndash;338\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWolf P (1967) The nature and significance of platelet products in human plasma. Br J Haematol 13:269\u0026ndash;288\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDos Reis DM, de Sa MF, de Moura MD et al (1999) Familial risk among patient with endometriosis. J Assist Reprod Genet 16:500\u0026ndash;503\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKashima K, Ishimaru T, Okamura H et al (2004) Familial risk among Japanese patient with endometriosis. Int J Gynaecol Obstet 84:61\u0026ndash;64\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStefansson H, Geirsson RT, Steinthorsdottir V et al (2002) Genetic factors contribute to the risk of developing endometriosis. Hum Reprod 17:555\u0026ndash;559\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZondervan KT, Weeks DE, Colman R et al (2004) Familial aggregation of endometriosis in large pedigree of rhesus macaques. Hum Rerod 19:448\u0026ndash;455\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlbertsen HM, Chettier R, Farrington P, Ward K (2013) Genome-wide association study link novel loci to endometriosis. PLoS ONE 8:e58257\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Export Rev Proteomics 6:267\u0026ndash;283\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHugel B, Mart\u0026iacute;nez MC, Kunzelmann C, Freyssinet JM (2005) Membrane microparticles: two sides of the coin, Physiology, vol.\u0026nbsp;20, pp.\u0026nbsp;22\u0026ndash;27,\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eValadi H, Ekstrom K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654\u0026ndash;659\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSkog J, Wurdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470\u0026ndash;1476\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePisetsky DS, Gauley J, Ullal AJ (2010) Microparticles as asource of extracellular DNA. Immunol Res\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIrungu S, Mavrelos D, Worthington J, Blyuss O, Saridogan E, Timms JF (2019 Apr) Discovery of non-invasive biomarkers for the diagnosis of endometriosis. Clin Proteom 6:16:14\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBallard K, Lowton K, Wright J (2006) What\u0026rsquo;s the delay? A qualitative study of women\u0026rsquo;s experiences of reaching a diagnosis of endometriosis. Fertil Steril 86(5):1296\u0026ndash;1301\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHadfield R, Mardon H, Barlow D, Kennedy S (1996) Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK. Hum Reprod 11(4):878\u0026ndash;880\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHusby GK, Haugen RS, Moen MH (2003) Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 82(7):649\u0026ndash;653\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKayama CM, Debrock S, Mwenda JM, D\u0026rsquo;Hooghe TM (2003) Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 1:123\u0026ndash;132\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMachado DE, Berardo PT, Palmero CY, Nasciutti LE (2010) Higher expression of vascular endothelial growth factor (VEGF) and35. its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is smaller to cancer disease. J Exp Clin Cancer Res 29:4\u0026ndash;13\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDziechciowski M, Zapala B, Skotniczny K et al (2018) Diagnostic and prognostic relevance of microparticles in peripheral and uterine blood of patients with endometrial cancer. Ginekol Pol 89(12):682\u0026ndash;687\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMancuso P, Calleri A, Cassi C et al (2003) Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522:83\u0026ndash;97\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeerepoot LV, Mehra N, Vermaat JSP et al (2004) Increased levels of viable circu-lating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1):139\u0026ndash;145\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMancuso P, Burlini A, Pruneri G et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97(11):3658\u0026ndash;3661\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNielsen CT, Ostergaard O, Stener L, Iversen LV, Truedsson L, Gullstrand B et al (2012) Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum 64:1227\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBiro E, Nieuwland R, Tak PP, Pronk LM, Schaap MCL, Sturk A et al (2007) Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 66:1085\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Eijk IC, Tushuizen ME, Sturk A, Dijkmans BA, Boers M, Voskuyl AE et al (2010) Circulating microparticles remain associated with complement activation despite intensive antiinflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis 69:1378\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRenner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE et al (2013) Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 24:1849\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYin W, Ghebrehiwet B, Peerschke EIB (2008) Expression of complement components and inhibitors on platelet microparticles. Platelets 19:225\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eY\u0026aacute;\u0026ntilde;ez-M\u0026oacute; M, Siljander PR, Andreu Z et al (2015) l.: Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. May 14;4:27066\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHargett LA, Bauer NN (2013) On the origin of microparticles: from \u0026lsquo;\u0026lsquo;platelet dust\u0026rsquo;\u0026rsquo; to mediators of intercellular communication. Pulm Circ 3:329\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCordazzo C, Neri T, Petrini S et al (2013) Angiotensin II induces the generation of procoagulant microparticles by human mononuclear cells via an angiotensin type 2 receptor-mediated pathway. Thromb Res 131:e168\u0026ndash;e174\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePreston RA, Jy W, Jimenez JJ et al (2003) Effects of severe hypertension on endothelial and platelet microparticles. Hypertens 41:211\u0026ndash;217\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHsu CY, Huang PH, Chiang CH et al (2013) Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients. PLoS ONE 8:e68644\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang PH, Huang SS, Chen YH et al (2010) Increased circulating CD31\u0026thorn;/annexin V \u0026thorn; apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 28:1655\u0026ndash;1665\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAyers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M et al (2011) Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res 127:370\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWitwer KW, Buz\u0026aacute;s EI, Bemis LT et al (2013) l.: Standardization of sample collection, isolation and analysis methods in extracellular vesicle research.J Extracell Vesicles. May 27;2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYoung TN, Rodriguez GC, Rinehart AR et al (1996) Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62:89\u0026ndash;99\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDolo V, D\u0026rsquo;Ascenzo S, Violini S et al (1999) Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17:131\u0026ndash;140\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVanDeun J, Mestdagh P, Sormunen R et al (2014) The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles 3:24858\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJy W, Horstman LL, Jimenez JJ et al (2004) Measuring circulating cell-derived microparticles. J Thromb Haemost 2(10):1842\u0026ndash;1851\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan der Pol E, Hoekstra AG, Sturk A et al (2010 Dec) Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost 8(12):2596\u0026ndash;2607\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDey-Hazra E, Hertel B, Kirsch T et al (2010 Dec) Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 6:6:1125\u0026ndash;1133\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChandler WL, Yeung W, Tait JF A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer.Journal of Thrombosis and Haemostasis, 9:1216\u0026ndash;122\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJy W, Horstman LL, Jimenez JJ et al (2004) Measuring circulating cell-derived microparticles. J Thromb Haemost 2(10):1842\u0026ndash;1851\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDaniel L, Fakhouri F, Joly D et al (2006) Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 69(8):1416\u0026ndash;1423\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLynch SF, Ludlam CA (2007) Plasma microparticles and vascular disorders. Br J Haematol 137(1):36\u0026ndash;48\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eErdbruegger U, Grossheim M, Hertel B et al (2008) Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford) 47(12):1820\u0026ndash;1825\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShah MD, Bergeron AL, Dong JF, Lopez JA (2008) Flow cytometric measurement of microparticles: Pitfalls and protocol modifications. Platelets 19(5):365\u0026ndash;372\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBuschmann D, Kirchner B, Hermann S et al (2019 Mar) Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing. Extracell Vesicles 08(1):1581487\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFilella M, Zhang JW, Newman ME, Buffle J (1997) Analytical applications of photon correlation spectroscopy for size distribution measurements of natural colloidal suspensions: capabilities and limitations. Colloids Surf A Physicochem Eng Asp 120:27\u0026ndash;46\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIto T, Sun L, Henriquez RR, Crooks RM (2004) A carbon nanotube-based coulter nanoparticle counter. Acc Chem Res 37:937\u0026ndash;945\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSaleh OA, Sohn LL (2001) Quantitative sensing of nanoscale colloids using a microchip Coulter counter. Rev Sci Instrum 72:4449\u0026ndash;4451\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJoop K, Berckmans RJ, Nieuwland R et al (2001) Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 85(5):810\u0026ndash;820\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNozaki T, Sugiyama S, Sugamura K et al (2010) Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail 12(11):1223\u0026ndash;1228\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang EG, Smith SK, Charnock-Jones DS (2002 Nov) Expression of CD105 (endoglin) in arteriolar endothelial cells of human endometrium throughout the menstrual cycle. Reproduction 124(5):703\u0026ndash;711\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI (1994) Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Resaerch 54:2347\u0026ndash;2358\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGhosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE (2010) : Circulating microvesicles in B cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood; 115(9):1755\u0026ndash;1764\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGyorgy B, Szabo TG, Turiak L et al (2012) Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases. PLoSONE 7(11):e49726\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu R, Klich I, Ratajczak J et al (2009) Erythrocyte-derived microvesicles may transfer phosphatidylserine to the surface of nucleated cells and falsely \u0026lsquo;mark' them as apoptotic. Eur J Haematol 83(3):220\u0026ndash;229\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVoukalis C, Shantsilaa E, Lip GYH Microparticles, and cardiovascular diseases, ANNALS OF MEDICINE 2019, VOL. 51, NOS. 3\u0026ndash;4, 193\u0026ndash;223\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConnor DE, Exner T, Ma DDF, Joseph JE (2010) The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 103(5):1044\u0026ndash;1052\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoulanger CM, Amabile N, Tedgui A (2006) Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 48(2):180\u0026ndash;186\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmabile N, Guerin AP, Leroyer A et al (2005) l.: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol ; 16(11):3381\u0026ndash;3388\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBudoni M, Fierabracci A, Luciano R et al (2013) The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transpl 22(2):369\u0026ndash;379\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTao H, Chen X, Wei A et al (2018) l.: Comparison of Teratoma Formation between Embryonic Stem Cells and Parthenogenetic Embryonic Stem Cells by Molecular Imaging Stem Cells Int. Mar 25;2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNg YH et al (2013c) Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation. PLoS ONE 8:e58502\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShomali N et al (2020) Exosomes: Emerging biomarkers and targets in folliculogenesis and endometriosis. J Reprod Immunol 142:103181\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarp D, Driss A, Mehrabi S et al (2016) Exosomes derived from endometriotic stromal cells have enhanced angiogenic effects in vitro. Cell Tissue Res 365:187\u0026ndash;196\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD\u0026rsquo;Alterio MN, Saponara S, Agus M et al (2021) Medical and surgical interventions to improve the quality of life for endometriosis patients: a systematic review. Gynecol Surg 18:13\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWu C-Y, Wu J-D, Chen C-C (2021) The Association of Ovarian Teratoma and Anti-N-Methyl-D-Aspartate Receptor Encephalitis: An Updated Integrative Review. Int J Mol Sci 22:10911\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThe members of the Endometriosis Guideline Core Group, Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N, ESHRE Endometriosis Guideline Group (2022), Issue 2, 2022, hoac009\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 5 and 6 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"archives-of-gynecology-and-obstetrics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"arch","sideBox":"Learn more about [Archives of Gynecology and Obstetrics](https://www.springer.com/journal/404)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/arch/default.aspx","title":"Archives of Gynecology and Obstetrics","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"endometriosis, microvesicles, angiogenesis, VEGF MMP-9","lastPublishedDoi":"10.21203/rs.3.rs-1707582/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1707582/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003ePurpose:\u0026nbsp;\u003c/strong\u003eAngiogenesis is engaged in endometriosis. It is regulated by regulatory factors and cytokines, transported in microvesicles. The purpose was to investigate the presence of MVs with vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP – 9) in peripheral blood and peritoneal fluid of women operated on for endometrioma or teratoma\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMaterial and method:\u0026nbsp;\u003c/strong\u003eMicrovesicles (MVs) were determined in blood samples and peritoneal fluid samples collected from women aged 20-60 years operated on for endometriosis (test group) and teratoma (control group). The final investigations were performed on 47 patients, who qualified for the study based on the meticulous inclusion criteria. MVs were analyzed by flow cytometry (FACS) using annexin V, antibodies for molecules characteristic of cells from endometriosis foci (keratin 18 (K18), CD105, CD146), and antibodies for intraepithelial vascular growth factor VEGF and metalloproteinase - 9 (MMP - 9). The sample was double “reading” using flow cytometry (FACSCantoII).\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults:\u0026nbsp;\u003c/strong\u003eCytometry analysis confirmed MVs’ presence in plasma and peritoneal fluid collected from patients with both endometriosis and teratomas. A statistically significant higher level of AnnexinV (+) MVs were observed in plasma samples of endometriosis patients. In the control group, there was a higher percentage of double-positive VEGF (+) / MMP9 (+) and single MMP9 (+) positive MVs in the serum. In the peritoneal fluid higher frequency of double-positive VEGF (+),/MMP9 (+) MVs were found in the control group. However, the amount of VEGF (+) / MMP9 (+) MVs object did not enable to differentiate between the test and control groups. The study was the first, in which MVs were confirmed in plasma and peritoneal fluid in benign adnexa tumors.\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: Microvesicles are present in peripheral blood and peritoneal fluid samples collected from patients with endometriosis and teratomas. Microvesicles with proangiogenic factors (VEGF and MMP-9) are more abundant in blood and peritoneal fluid samples from patients with teratomas.\u003c/p\u003e","manuscriptTitle":"Microvesicles released from ectopic endometrial foci as a potential biomarker of endometriosis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-07-05 17:23:05","doi":"10.21203/rs.3.rs-1707582/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"","date":"2022-07-11T10:10:23+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2022-06-27T06:01:40+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"Archives of Gynecology and Obstetrics","date":"2022-06-26T13:31:20+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2022-06-06T03:13:32+00:00","index":"","fulltext":""},{"type":"submitted","content":"Archives of Gynecology and Obstetrics","date":"2022-05-30T06:46:46+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"archives-of-gynecology-and-obstetrics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"arch","sideBox":"Learn more about [Archives of Gynecology and Obstetrics](https://www.springer.com/journal/404)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/arch/default.aspx","title":"Archives of Gynecology and Obstetrics","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"473056f9-9e66-4df7-a34a-0e888a0f5304","owner":[],"postedDate":"July 5th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2022-07-05T17:23:05+00:00","versionOfRecord":[],"versionCreatedAt":"2022-07-05 17:23:05","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1707582","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1707582","identity":"rs-1707582","version":["v1"]},"buildId":"WvIrzKhiLBfengagbw6Ux","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}